Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
Organizer:

The urgency of the highly interrelated TB and HIV/AIDS epidemics has prompted calls for a rapid and robust scale-up of TB and HIV vaccine research efforts and close collaboration between TB and HIV vaccine development programs. Those at risk for TB and HIV need more choices in prevention to circumvent structural, societal and cultural factors that hinder access and adherence. This session will discuss the importance of vaccine development and deployment to conclusively end HIV/AIDS and TB; it will describe the progress already made, as well as the challenges faced, and the potential for enhanced collaboration between TB and HIV vaccine researchers and developers. This session is targeted to researchers, policymakers, healthcare providers, product developers, civil society, and other stakeholders interested in ending the TB and HIV/AIDS epidemics.

08:00
MOSA0401
Breakfast
08:10
MOSA0402
Welcome and Introduction
Jacqueline Shea, Aeras, United States
08:15
MOSA0403
State of the Field and Future Direction of Research and Development for TB and HIV/AIDS Vaccines
Glenda Gray, South African Medical Research Council, South Africa
Slides
08:40
MOSA0404
Panel Discussion
Amb. Eric Goosby, UN Special Envoy on Tuberculosis and University of California San Francisco Global Health Sciences, United States
Ruth Labode, Parliament of Zimbabwe, Zimbabwe
Glenda Gray, South African Medical Research Council, South Africa
Peter Godfrey-Faussett, UNAIDS, Switzerland
Nomampondo Barnabas, International Union Against Tuberculosis and Lung Disease (The Union), South Africa
09:25
MOSA0405
Concluding Remarks
Amb. Eric Goosby, UN Special Envoy on Tuberculosis and University of California San Francisco Global Health Sciences, United States
09:30
MOSA0406
Discussion and Q&A
Mitchell Warren, AVAC, United States